Glycotope is a clinical stage immuno-oncology company built on world-leading glyco-biology expertise. We focus primarily on developing innovative immuno-oncology products for the treatment of a range of cancer types. In addition our proprietary technologies have been used to develop treatments for infertility and blood coagulation disorders. Glycotope was founded in 2001 in Berlin, Germany.

By leveraging our proprietary technologies, we are driving a pipeline of first-in-class biopharmaceuticals that are highly specific and highly potent.

GET enables us to identify and target specific glyco-epitopes found on tumor cells.

GEX® enables the glyco-optimisation of fully human glycosylated biopharmaceuticals that have the potential for enhanced efficacy and fewer side effects.

Using these unique technologies Glycotope has developed a mature and growing pipeline of proprietary cancer therapies, as well as products in infertility and blood coagulation. Our lead oncology product, Gatipotuzumab (previously known as PankoMab-GEX®), has potential in a number of oncology indications and has recently completed a Phase 2 trail for TAMUC1-positive ovarian cancer. We also have two further oncology products in Phase 1 and Phase 2 development.

With our world-leading expertise in glyco-biology, unique platform technologies, and our experienced management team and board, we believe our promising pipeline will deliver more effective treatments with fewer side effects and, ultimately, improve outcomes for patients.

Our strategy is to seek collaboration partners for late-stage development and commercialization for our oncology products, and partners to out-license existing clinical programs in our non-oncology portfolio.


At Glycotope, we aim to play our part in the immuno-oncology revolution by using our world-leading understanding of glyco-biology to develop new and better targeted and glyco-optimized immunotherapeutics in cancer and other areas of high unmet medical need. "
Henner Kollenberg
Managing Director